Nine military patients with chronic PTSD were treated with stellate ganglion block. All of the patients had been treated for over a year in programs that used selective serotonin reuptake inhibitors, individual psychotherapy (cognitive processing therapy or prolonged exposure therapy), and other evidence-based treatments. They were in the process of being medically retired from the military, and they were all aware that stellate ganglion block was offered as an off-label indication and gave informed consent to the treatment. The patients were not required to stop any other treatment to receive the stellate ganglion block, and all chose to continue their medications. For stellate ganglion block, fluoroscopic and ultrasound guidance were used with a lateral or paratracheal approach. Ropivacaine, 7 mL of a 0.5% solution, was injected following negative aspiration and negative test dose. Injection was performed at the C6 level, which was confirmed by observing the position of contrast dye, but medication may have spread to the level(s) above and below. Minimal sedation guidelines were followed, and sterile technique was used. PTSD symptoms were assessed using the CAPS before the procedure and 1 week after stellate ganglion block. Outcomes were tracked after a single injection in seven patients, and a second treatment was performed 4 to 6 weeks later in two patients.